Abstract:Background: CNS involvement (CNSi) is a rare and often fatal event, occurring in around 5% of patients (pts) with diffuse large B-cell lymphoma (DLBCL) during primary treatment or shortly after completion (SCNSL). Furthermore, the potential mechanisms of CNS dissemination were limited. Circulating tumor DNA from cerebrospinal fluid (CSF-ctDNA) has played an important part in the application of liquid biopsy in CNS cancers. In this study, we provided new insights into the feasibility of using CSF-ctDNA as an essential tool for CNSi diagnosis, treatment, and evaluation specifically in newly diagnosed (ND) DLBCL pts. Methods : Between December 2021 and April 2023, 168 ND DLBCL pts and 24 ND PCNSL pts have been treated in our center. One hundred DLBCL pts were enrolled in the training cohort while the other 68 pts refused to enter in our study. Another 26 ND DLBCL pts diagnosed between May 2023 and June 2023 were entered into a validation cohort. The flow of treatment and samples collections were according to the study protocol shown in Figure 1A. CSF-ctDNA positive (CSF-ctDNA(+)) criteria: (1) CSF-ctDNA detected mutations consistent with tissue; (2) Mutations detected in CSF-ctDNA were inconsistent with tissues, but were classified as grade I and grade II mutations; (3) At least one mutation was detected with an abundance >0.5%. The criteria of CNSi positive (CNSi(+)) were CSF-ctDNA(+) or/and other evidences detected by conventional methods (CM, including MRI, PET-CT, routine inspection analysis of CSF). Results: In the training cohort, 25 pts (25%) were diagnosed with CSF-ctDNA (+) while 21 pts were according to the first criteria and 4 pts were according to the second criteria. Among the 25 pts (25.0%) who were finally diagnosed with CNSi (+), only 3 pts (12.0%) have evidences of CNSi both in CM and CSF-ctDNA while similar results were shown in validation cohort ( Figure 1B). The unique mutations detected in CSF were rare compared with plasma and tissue mainly due to early detection with no clone evolution ( Figure 1C). The mean variant allele frequency was significantly higher in tumor tissue than CSF in SCNSL ( Figure 1D). The pretreatment ctDNA burden was significantly higher in CSF of PCNSL while higher in plasma of SCNSL ( Figure 1F). The distributions of gene subtypes for the 25 CNSi (+) DLBCL pts were shown in Figure 1E. Only 11 pts (44%) were MCD subtype while nearly 80% PCNSL pts were MCD subtype. There existed significant differences of gene mutation profile between SCNSL and PCNSL ( Figure 1G). We explored the association of clinical and biological factors with CNSi in ND DLBCL pts . Of note, high plasma ctDNA burden (≥2.18) were significantly related to CNSi (+) (Figure 1H). In multivariable analyses, CSF protein level ≥0.4, high plasma ctDNA burden (≥2.18) and high risk CNSi sites involvement were independent risk factors for CNSi ( Figure 1I). We use these 3 risk factors to build CNSi-IPI model which can significantly better predict CNSi than CNS-IPI ( Figure 1I). According to CNSi-IPI, pts were stratified into low-risk (0-1), intermediate-risk (2) and high-risk (3). CNSi (+) were observed in 5.0%, 48.3% and 72.7% in the training cohort and 5.9%, 50.0% and 100.0% in the validation cohort in the 3 risk groups ( Figure 1J). Pts with CARD11, JAK2, ID3, and PLCG2 mutation were more predominant with CNSi while FAT4 mutation seemed to promote tumor cells disseminating to CNS ( Figure 1K). Furthermore, the down-regulated genes of CNSi DLBCL pts significantly enriched in PI3K-AKT signaling pathway, focal adhesion, regulation of action cytoskeleton and tight junction pathways, which might be the potential mechanisms promoting CNS dissemination in ND DLBCL ( Figure 1L). The dynamic change of disease status and ctDNA burden of all the 25 CNSi (+) pts were shown in Table 1. Conclusion :In summary, our study highlighted the clinical implications of CSF-ctDNA in CNSi detection of ND DLBCL pts ( Figure 1M): (1) CSF-ctDNA exhibits higher sensitivity than CM in detecting CNSi in ND DLBCL. (2) Different genomic and clinical landscapes were observed between SCNSL and PCNSL. (3) The CNSi-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNSi in ND DLBCL. (4) Down-regulation of PI3K-AKT signaling pathway, focal adhesion, regulation of action cytoskeleton and tight junction pathways contribute to CNS dissemination in ND DLBCL. (5) Furthermore, CSF-ctDNA can be used to monitor CNS tumor burden and response to treatment.

Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma

Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Integration of Cell of Origin into the Clinical CNS International Prognostic Index Improves CNS Relapse Prediction in DLBCL.

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma

Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma

Cell-Free DNA in Cerebrospinal Fluid Complements the Monitoring Value of Interleukin-10 in Newly Diagnosed Primary Central Nervous System Lymphoma

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

Circulating Tumor DNA Clearance During Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

Analysis of CCND3 mutations in diffuse large B-cell lymphoma

Biom-61. Csf Ctdna Analysis Of Patients With Diffuse Gliomas Reveals Diagnostic Molecular Alterations

Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification

Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas